Drug Trial Radar · NCT07285213
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Dec 10, 2025
Primary completion
Apr 20, 2027
Study completion Jan 18, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
Conditions
- Clostridioides Difficile Infection
Interventions
AZD5148Drug
Participants will receive a single dose A of AZD5148 administered via either intramuscular injection or intravenous push.
PlaceboOther
Participants will receive a single dose of placebo (0.9% (w/v) sodium chloride for injection) administered via either intramuscular injection or intravenous push.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First occurrence of recurrence of C difficile infectionTime frame: Day 1 through day 91
Locations
117 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Withdrawn
Research Site
Chula Vista, California · Withdrawn
Research Site
Sacramento, California · Recruiting
Research Site
Torrance, California · Recruiting
Research Site
Hamden, Connecticut · Recruiting
Research Site
Gainesville, Florida · Withdrawn
Research Site
Hialeah, Florida · Recruiting
Research Site
Homestead, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Miami Lakes, Florida · Withdrawn
Research Site
Miramar, Florida · Withdrawn
Research Site
Port Orange, Florida · Withdrawn
Research Site
Tamarac, Florida · Withdrawn
Research Site
Tampa, Florida · Withdrawn
Research Site
Athens, Georgia · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Idaho Falls, Idaho · Recruiting
Research Site
Burr Ridge, Illinois · Recruiting
Research Site
Lexington, Kentucky · Withdrawn
Research Site
Louisville, Kentucky · Recruiting
Research Site
New Orleans, Louisiana · Recruiting
Research Site
Glen Burnie, Maryland · Recruiting
Research Site
Potomac, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Royal Oak, Michigan · Recruiting
Research Site
Columbia, Missouri · Recruiting
Research Site
Kansas City, Missouri · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Union City, New Jersey · Recruiting
Research Site
Hartsdale, New York · Withdrawn
Research Site
Inwood, New York · Withdrawn
Research Site
The Bronx, New York · Withdrawn
Research Site
Salisbury, North Carolina · Recruiting
Research Site
Winston-Salem, North Carolina · Recruiting
Research Site
Pittsburgh, Pennsylvania · Withdrawn
Research Site
Johnson City, Tennessee · Recruiting
Research Site
Charlottesville, Virginia · Recruiting
Research Site
Lynchburg, Virginia · Recruiting
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.